BriaCell’s Phase 2 Study Shows Promising Survival Data in Breast Cancer

BriaCell Therapeutics ( (TSE:BCT) ) has provided an announcement.

BriaCell Therapeutics has announced positive survival data from its Phase 2 study of Bria-IMT plus checkpoint inhibitors, showing a median overall survival of 17.3 months in hormone receptor positive metastatic breast cancer patients, surpassing the 14.4 months associated with the current standard, TRODELVY. This development suggests a promising therapeutic option for HR+ and triple-negative breast cancer patients, potentially addressing unmet medical needs and offering a well-tolerated treatment alternative.

Spark’s Take on TSE:BCT Stock

According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Underperform.

BriaCell Therapeutics’ overall score reflects a challenging financial position with no revenue and consistent losses, posing significant risks. The bearish technical indicators add to the negative outlook. However, promising corporate developments in cancer treatment and strategic financing efforts provide some potential upside.

To see Spark’s full report on TSE:BCT stock, click here.

More about BriaCell Therapeutics

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care.

YTD Price Performance: -56.21%

Average Trading Volume: 12,066

Technical Sentiment Signal: Buy

Current Market Cap: C$22.26M

Learn more about BCT stock on TipRanks’ Stock Analysis page.